Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Namilumab in RA (NEXUS)
NCT02379091Phase 2Completed
- Sponsor
- Takeda
- Start
- Dec 2014
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of namilumab in rheumatoid arthritis (RA) (4 arms), sponsored by Takeda. Primary endpoint: Disease Activity Score 28 C-Reactive Protein at 12 weeks. Started Dec 2014; status: completed.
02
Drugs
namilumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02379091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02379091.